Glioblastoma Multiforme News and Research

RSS

Glioblastoma Multiforme is a fast-growing type of central nervous system tumor that forms from glial (supportive) tissue of the brain and spinal cord and has cells that look very different from normal cells. Glioblastoma multiforme usually occurs in adults and affects the brain more often than the spinal cord. Also called GBM, glioblastoma, and grade IV astrocytoma.

New graphene system can detect activity levels of interfaced normal and cancer cells

What can't graphene do? You can scratch "detect cancer" off of that list. By interfacing brain cells onto graphene, researchers at the University of Illinois at Chicago have shown they can differentiate a single hyperactive cancerous cell from a normal cell, pointing the way to developing a simple, noninvasive tool for early cancer diagnosis.

20 Dec 2016

Researchers identify attractive drug candidate to target glioma tumors

In a paper published today in Cancer Research, researchers: 1) identify a biomarker enzyme associated with aggressive glioma brain tumors, 2) reveal the regulatory mechanism for that enzyme, and 3) demonstrate potent efficacy, using a mouse model of glioma, for a small molecule inhibitor they have developed.

16 Dec 2016

Researchers design smart drug to treat patients with most aggressive brain cancers

Physicians and researchers at Houston Methodist Hospital have designed a new drug to treat patients with the most aggressive, incurable brain cancers.

21 Nov 2016

Researchers identify pathway that helps cancer cells to aggressively spread in the brain

Glioblastoma multiforme remains the most common and highly lethal brain cancer and is known for its ability to relapse.

17 Nov 2016

UPV participates in Lumiblast project to develop novel treatments for hard-to-treat brain tumours

The Polytechnic University of Valencia is taking part in Lumiblast, a European project to develop an innovative approach to hard-to-treat brain tumours like glioblastomas.

14 Oct 2016

UCLA scientists develop statistical method for conducting survival analysis of cancer patients

People with cancer are often told by their doctors approximately how long they have to live, and how well they will respond to treatments, but what if there were a way to improve the accuracy of doctors' predictions?

9 Jun 2016

Specific immune system genes may determine how long people can live with glioblastoma

Researchers have identified a group of immune system genes that may play a role in how long people can live after developing a common type of brain cancer called glioblastoma multiforme, a tumor of the glial cells in the brain.

26 May 2016

Clinical trials of anti-cancer agent PAC-1 continue to progress with anonymous funding

Clinical trials of the anti-cancer agent PAC-1 are continuing to expand, thanks to a $7 million angel investment from an anonymous contributor who originally invested $4 million to help get the compound this far in the drug-approval pipeline.

25 May 2016

Mitoxantrone for MS linked to colorectal cancer risk

Treatment with mitoxantrone for multiple sclerosis carries only a mildly increased risk of malignancy overall, but the risk of colorectal cancer and leukaemia is heightened, researchers have found.

24 May 2016

Small lipid nanocarrier may deliver chemotherapeutic drug more efficiently to brain tumor cells

Great discoveries do come in small packages. Few know that better than Ann-Marie Broome, Ph.D., who feels nanotechnology holds the future of medicine with its ability to deliver powerful drugs in tiny, designer packages.

23 May 2016

Scientists examine PD-1-expressing regulatory T cells in aggressive brain cancer

Immunotherapy represents an exciting advance in cancer treatment that harnesses the immune system to seek and destroy cancer cells.

22 Apr 2016

DelMar's VAL-083 receives FDA orphan drug designation for treatment of medulloblastoma

DelMar Pharmaceuticals, Inc., announced today that the FDA Office of Orphan Products Development (OOPD) has granted orphan drug designation for its lead product candidate, VAL-083, in the treatment of medulloblastoma.

15 Mar 2016

Expression of BIRC3 protein associated with poor survival, recurrent disease in GBM patients

Glioblastoma multiforme (GBM) is a highly aggressive brain tumor with low survival rates, with newly diagnosed patients surviving a median of 14 months and recurrent patients surviving a median of only 3 to 9 months. New therapeutic targets and biomarkers for prognosis are urgently needed.

7 Mar 2016

U-M researchers develop novel mouse model of children's brain cancer

Children with brain cancer may soon get some help from mice with the same disease, thanks to new research from University of Michigan Medical School scientists and their colleagues.

3 Mar 2016

EMA grants Orphan Drug Designation to venetoclax for treatment of acute myeloid leukemia

AbbVie, a global biopharmaceutical company, today announced the European Medicines Agency has granted Orphan Drug Designation to venetoclax, an investigational, oral B-cell lymphoma-2 (BCL-2) inhibitor, for the treatment of acute myeloid leukemia (AML).

26 Feb 2016

Researchers make some progress in determining causes for glioblastoma multiforme

A research team, with the participation of the University of Granada (UGR), has made some progress in determining the causes for glioblastoma multiforme (GBM), one of the most aggressive brain tumors known, to be resistant to the drugs currently used, which is one of the main limitations of its treatment.

18 Feb 2016

West Cancer Center introduces promising new treatment method for brain cancer patients

Brain Cancer patients in the Mid-South now have a promising new treatment method at West Cancer Center. Optune™, a portable device using low intensity electric fields to inhibit cancer cell replication causing death of cancer cells, is the first FDA-approved therapy in more than a decade to show a significant extension in overall survival rates for newly diagnosed adult Glioblastoma Multiforme (GBM) patients.

11 Feb 2016

Salk Institute scientists find new target for glioblastoma multiforme treatment

Glioblastoma multiforme is a particularly deadly cancer. A person diagnosed with this type of brain tumor typically survives 15 months, if given the best care. The late Senator Ted Kennedy succumbed to this disease in just over a year.

11 Jan 2016

Researchers reveal specific enzyme responsible for sensing energy source that fuels growth of cancer cells

An international research team formed by a University of Cincinnati cancer researcher has shown for the first time that a specific enzyme is responsible for sensing the available supply of GTP, an energy source that fuels the uncontrolled growth of cancer cells. The research underscores the enzyme's potential to become a therapeutic target for future cancer drugs.